Molecular profiling and combinatorial activity of CCT068127: A potent CDK2 and CDK9 inhibitor

Autor: Whittaker, Steven R., Barlow, Clare, Martin, Mathew P., Mancusi, Caterina, Wagner, Steve, Self, Annette, Barrie, Elaine, Te Poele, Robert, Sharp, Swee, Brown, Nathan, Wilson, Stuart, Jackson, Wayne, Fischer, Peter M., Clarke, Paul A., Walton, Michael I., McDonald, Edward, Blagg, Julian, Noble, Martin, Garrett, Michelle D., Workman, Paul

Publikováno v: Molecular Oncology, Vol 12, Iss 3, Pp 287-304 (2018)
Molecular Oncology

Deregulation of the cyclin-dependent kinases (CDKs) has been implicated in the pathogenesis of multiple cancer types. Consequently, CDKs have garnered intense interest as therapeutic targets for the treatment of cancer. We describe herein the molecul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1d382ee9a2198b5c395c2b8cf3b0e572

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

GOODBYE, VITAMIN.

Autor: Barrie, Elaine

Publikováno v: AudioFile. Dec2017/Jan2018, Vol. 26 Issue 4, p33-33. 1/6p. 1 Color Photograph.

Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.

Autor: Whittaker SR; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Barlow C; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Martin MP; Northern Institute for Cancer Research, University of Newcastle upon Tyne, Medical School, Newcastle upon Tyne, UK., Mancusi C; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Wagner S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Self A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Barrie E; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Te Poele R; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Sharp S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Brown N; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Wilson S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Jackson W; Cyclacel Ltd., Dundee, UK., Fischer PM; Cyclacel Ltd., Dundee, UK., Clarke PA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Walton MI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., McDonald E; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Blagg J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Noble M; Northern Institute for Cancer Research, University of Newcastle upon Tyne, Medical School, Newcastle upon Tyne, UK., Garrett MD; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Workman P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.

Publikováno v: Molecular oncology [Mol Oncol] 2018 Mar; Vol. 12 (3), pp. 287-304. Date of Electronic Publication: 2018 Jan 28.